

Revision date: 15-Apr-2014

Version: 2.0

## 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

**Product Identifier** 

Material Name: Triple-ET Innovator

| Trade | Name: |
|-------|-------|
| Synor | iyms: |

**Chemical Family:** 

Triple-ET Innovator Equine Encephalomyelitis Virus (Venezuelan, Eastern and Western strains) Vaccine (killed virus) and Tetanus Toxoid vaccine Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against Intended Use: Veterinary Vaccine

Details of the Supplier of the Safety Data Sheet

Zoetis Inc. 100 Campus Drive, P.O. Box 651 Florham Park, New Jersey 07932 (USA) Rocky Mountain Poison Control Center Phone: 1-866-531-8896 Product Support/Technical Services Phone: 1-800-366-5288

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: VMIPSrecords@zoetis.com Zoetis Belgium S.A. Mercuriusstraat 20 1930 Zaventem Belgium

Emergency telephone number: International CHEMTREC (24 hours): +1-703-527-3887

## 2. HAZARDS IDENTIFICATION

room and the appropriate therapy instituted.

Non-Hazardous Substance. Non-Dangerous Goods.

Appearance: Reddish-white opaque liquid Classification of the Substance or Mixture GHS - Classification Not classified as hazardous

EU Classification:

EU Indication of danger: Not classified

Label Elements

Signal Word: Hazard Statements: Not Classified Not classified in accordance with international standards for workplace safety.

Other Hazards Short Term:

Australian Hazard Classification (NOHSC):

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

May cause eye and skin irritation. In the event of accidental injection, an allergic reaction may occur. If an allergic reaction occurs, the worker should be removed to the nearest emergency

# **3. COMPOSITION/INFORMATION ON INGREDIENTS**

| Ingredient     | CAS Number | EU<br>EINECS/ELINCS<br>List | EU Classification                                | GHS<br>Classification  | %  |
|----------------|------------|-----------------------------|--|--|----|
| Neomycin B     | 119-04-0   | 204-292-2                   | Xn;R22<br>Xn;R42/43<br>Repr.Cat.3;R63            | Acute Tox. 4;H302<br>Resp. Sens.<br>1;H334<br>Skin Sens.1;H317<br>Repr.2;H361  | ## |
| Amphotericin B | 1397-89-3  | 215-742-2                   | Not Listed                                       | Not Listed   | ## |
| Polymyxin B    | 1404-26-8  | 215-768-4                   | Xn;R22<br>Xn;R42/43                              | Acute Tox. 4<br>(H302)<br>Skin Sens. 1<br>(H317)<br>Resp Sens. 1<br>(H334)   | ## |
| Formaldehyde   | 50-00-0    | 200-001-8                   | T; R23/24/25<br>C; R34<br>Carc.Cat.3; R40<br>R43 | Acute Tox. 3<br>(H301)<br>Skin Corr. 1B<br>(H314)<br>Skin Sens. 1<br>(H317)<br>Carc. 1A (H350)<br>Acute Tox. 3<br>(H331)                                   | ## |
| Thimerosal     | 54-64-8    | 200-210-4                   | T+; R26/27/28;<br>R33<br>N; R50/53               | Acute Tox. 2<br>(H300)<br>Acute Tox. 1<br>(H310)<br>STOT RE 2 (H373)<br>Acute Tox. 2<br>(H330)<br>Acute Aquatic 1<br>(H400)<br>Chronic Aquatic 1<br>(H410) | ## |

| Ingredient                           | CAS Number   | EU<br>EINECS/ELINCS<br>List | EU Classification | GHS<br>Classification | % |
|--------------------------------------|--------------|-----------------------------|-------------------|-----------------------|---|
| WESTERN EQUINE<br>ENCEPHALOMYELITIS  | Not Assigned | Not Listed                  | Not Listed        | Not Listed            | * |
| Tetanus toxoid                       | 93384-51-1   | 297-262-3                   | Not Listed        | Not Listed            | * |
| Adjuvant                             | NA           | Not Listed                  | Not Listed        | Not Listed            | * |
| Venezuelan Equine Enchephalomyelitis | Not Assigned | Not Listed                  | Not Listed        | Not Listed            | * |
| EASTERN EQUINE<br>ENCEPHALOMYELITIS  | Not Assigned | Not Listed                  | Not Listed        | Not Listed            | * |

#### **Additional Information:**

\* Proprietary

## Trace

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

# **4. FIRST AID MEASURES**

| Description of First Aid Measures<br>Eye Contact:   | Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.   |
|---|--|
| Skin Contact:   | Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.  |
| Ingestion:  | Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.                 |
| Inhalation:   | Remove to fresh air and keep patient at rest. Seek medical attention immediately.  |
| Most Important Symptoms and Effe<br>Symptoms and Effects of<br>Exposure:<br>Medical Conditions<br>Aggravated by Exposure: | cts, Both Acute and Delayed<br>For information on potential signs and symptoms of exposure, See Section 2 - Hazards<br>Identification and/or Section 11 - Toxicological Information.<br>None known |
| Indication of the Immediate Medical<br>Notes to Physician:  | Attention and Special Treatment Needed None  |
|   | 5. FIRE-FIGHTING MEASURES  |
| Extinguishing Media:  | Extinguish fires with CO2, extinguishing powder, foam, or water.   |
|   |  |
| Special Hazards Arising from the So<br>Hazardous Combustion<br>Products:  | Jbstance or Mixture<br>Formation of toxic gases is possible during heating or fire.  |
| Fire / Explosion Hazards:   | Fine particles (such as dust and mists) may fuel fires/explosions.   |
| Advice for Fire-Fighters<br>During all fire fighting activities,  | wear appropriate protective equipment, including self-contained breathing apparatus.   |
| 6.  | ACCIDENTAL RELEASE MEASURES  |
|   | quipment and Emergency Procedures<br>should wear appropriate personal protective equipment (see Section 8). Minimize exposure.   |
| Environmental Precautions<br>Place waste in an appropriately  | labeled, sealed container for disposal. Care should be taken to avoid environmental release.   |
| Methods and Material for Containm<br>Measures for Cleaning /<br>Collecting:   | ent and Cleaning Up<br>Contain the source of the spill if it is safe to do so. Wipe up with a damp cloth and place in<br>container for disposal. Clean contaminated surface thoroughly.            |
| Additional Consideration for<br>Large Spills:   | Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.                       |

# 7. HANDLING AND STORAGE

### **Precautions for Safe Handling**

#### Material Name: Triple-ET Innovator Revision date: 15-Apr-2014

Page 4 of 11 Version: 2.0

### 7. HANDLING AND STORAGE

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. Wash thoroughly after handling. Prevent environmental releases. Use appropriate personal protective equipment. Avoid accidental injection.

#### Conditions for Safe Storage, Including any Incompatibilities Storage Conditions: Store at room temperatu

Store at room temperature in properly labeled containers. Keep away from heat, sparks and flames.

Specific end use(s):

### No data available

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

100µg/m<sup>3</sup>Sensitizer

#### **Control Parameters**

Refer to available public information for specific member state Occupational Exposure Limits.

### Neomycin B Zoetis OEL TWA 8-hr

| Formaldehyde  |      |
|---------------|------|
| ACGIH Ceiling | Thre |

| malacityac                              |   |
|---|---|
| ACGIH Ceiling Threshold Limit:          | 0.3 ppm   |
| ACGIH - Sensitizer Designation          | Sensitizer  |
| Australia STEL                          | 2 ppm   |
|   | 2.5 mg/m <sup>3</sup>   |
| Australia TWA                           | 1 ppm   |
|   | 1.2 mg/m <sup>3</sup>   |
| Austria OEL - MAKs                      | 0.5 ppm   |
|   | 0.6 mg/m <sup>3</sup>   |
| Bulgaria OEL - TWA                      | 1.0 mg/m <sup>3</sup>   |
| Czech Republic OEL - TWA                | 0.5 mg/m <sup>3</sup>   |
| Estonia OEL - TWA                       | 0.5 ppm   |
|   | 0.6 mg/m <sup>3</sup>   |
| Finland OEL - TWA                       | 0.3 ppm   |
|   | 0.37 mg/m <sup>3</sup>  |
| France OEL - TWA                        | 0.5 ppm   |
| Germany (DFG) - MAK                     | 0.3 ppm   |
|   | 0.37 mg/m <sup>3</sup> no irritation should occur during mixed exposure |
| Greece OEL - TWA                        | 2 ppm   |
|   | 2.5 mg/m <sup>3</sup>   |
| Hungary OEL - TWA                       | 0.6 mg/m <sup>3</sup>   |
| Ireland OEL - TWAs                      | 2 ppm   |
|   | 2.5 mg/m <sup>3</sup>   |
| Japan - OELs - Ceilings                 | 0.2 ppm   |
|   | 0.24 mg/m <sup>3</sup>  |
| Latvia OEL - TWA                        | 0.5 mg/m <sup>3</sup>   |
| Lithuania OEL - TWA                     | 0.5 ppm   |
|   | 0.6 mg/m <sup>3</sup>   |
| Netherlands OEL - TWA                   | 0.15 mg/m <sup>3</sup>  |
| Vietnam OEL - TWAs                      | 0.5 mg/m <sup>3</sup>   |
| OSHA - Final PELS - TWAs:               | 0.75 ppm  |
| OSHA - Specifically Regulated Chemicals | 2 ppm   |
|   | 0.5 ppm   |
|   | 0.75 ppm  |
| Poland OEL - TWA                        | 0.5 mg/m <sup>3</sup>   |
| Romania OEL - TWA                       | 1 ppm   |
|   | 1.20 mg/m <sup>3</sup>  |
|   |   |

| 8. EXPOSURE CONTROLS / PERSONAL PROTECTION |                                   |  |
|--|-----------------------------------|--|
| Slovakia OEL - TWA                         | 0.3 ppm<br>0.37 mg/m³             |  |
| Slovenia OEL - TWA                         | 0.5 ppm<br>0.62 mg/m³             |  |
| Sweden OEL - TWAs                          | 0.3 ppm<br>0.37 mg/m <sup>3</sup> |  |
| Switzerland OEL -TWAs                      | 0.3 ppm<br>0.37 mg/m <sup>3</sup> |  |

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

| Polymyxin B<br>Zoetis OEB         | OEB 2 - Sensitizer (control exposure to the range of 100ug/m <sup>3</sup> to < 1000ug/m <sup>3</sup> , provide additional precautions to protect from skin contact)  |
|-----------------------------------|--|
| Exposure Controls                 |  |
| Engineering Controls:             | Engineering controls should be used as the primary means to control exposures. Use process containment, local exhaust ventilation, or other engineering controls to maintain airborne levels within the OEB range.   |
| Personal Protective<br>Equipment: | Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).  |
| Hands:                            | Wear impervious gloves if skin contact is possible.  |
| Eyes:                             | Safety glasses or goggles  |
| Skin:                             | Use protective clothing (uniforms, lab coats, disposable coveralls, etc.) in both production and laboratory areas.   |
| Respiratory protection:           | If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear<br>an appropriate respirator with a protection factor sufficient to control exposures to the bottom of<br>the OEB range. |

# 9. PHYSICAL AND CHEMICAL PROPERTIES

| Physical State:<br>Odor:<br>Molecular Formula:  | Liquid<br>Odorless<br>Mixture   | Color:<br>Odor Threshold:<br>Molecular Weight: | Reddish-white<br>No data available.<br>Mixture |
|---|---|--|--|
| Solvent Solubility:<br>Water Solubility:<br>pH:<br>Melting/Freezing Point (°C):<br>Boiling Point (°C):<br>Partition Coefficient: (Method, pH, E<br>No data available<br>Decomposition Temperature (°C): | No data available<br>Soluble<br>6-8<br>No data available<br>No data available.<br><b>Indpoint, Value)</b><br>No data available. |  |  |
| Evaporation Rate (Gram/s):<br>Vapor Pressure (kPa):<br>Vapor Density (g/ml):<br>Relative Density:<br>Viscosity:   | No data available<br>No data available<br>No data available<br>No data available<br>No data available                           |  |  |

Material Name: Triple-ET Innovator Revision date: 15-Apr-2014 Page 6 of 11 Version: 2.0

#### Flammablity:

Autoignition Temperature (Solid) (°C): Flammability (Solids): Flash Point (Liquid) (°C): Upper Explosive Limits (Liquid) (% by Vol.): Lower Explosive Limits (Liquid) (% by Vol.): No data available No data available No data available No data available No data available

# **10. STABILITY AND REACTIVITY**

Reactivity: Chemical Stability: Possibility of Hazardous Reactions Oxidizing Properties: Conditions to Avoid: Incompatible Materials: Hazardous Decomposition Products:

No data available Stable under normal conditions of use.

No data available Fine particles (such as dust and mists) may fuel fires/explosions. As a precautionary measure, keep away from strong oxidizers No data available

### **11. TOXICOLOGICAL INFORMATION**

#### Information on Toxicological Effects General Information:

Toxicological properties of the formulation have not been fully investigated. The antigens included in this product are non-infectious. All have been prepared from killed or inactivated preparations of microorganisms. The information included in this section describes the potential hazards of the individual ingredients.

### Acute Toxicity: (Species, Route, End Point, Dose)

#### Thimerosal

Rat Oral LD50 75 mg/kg Mouse Oral LD50 91 mg/kg Rat Subcutaneous LD50 98mg/kg

#### **Neomycin B**

Rat Oral LD 50 1250 mg/kg Mouse IV LD50 24mg/kg

#### Formaldehyde

Rat Oral LD50 800 mg/kg

#### **Polymyxin B**

Mouse Oral LD50 790 mg/kg Mouse Para-periosteal LD50 3980ug/kg Rat Subcutaneous LD50 50mg/kg

#### **Amphotericin B**

> 5000 mg/kg Rat Oral LD50 LD50 Rat Para-periosteal 1.6mg/kg Intraperitoneal LD50 > 5000mg/kg Rat Mouse Intravenous LD50 1.2mg/kg Mouse Intraperitoneal LD50 27.7mg/kg

## **11. TOXICOLOGICAL INFORMATION**

#### Irritation / Sensitization: (Study Type, Species, Severity)

#### Thimerosal

Eye Irritation Rabbit Mild

#### Formaldehyde

Eye Irritation Rabbit Severe Skin Irritation Rabbit Moderate Severe Skin Sensitization Positive

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

#### Formaldehyde

90 Day(s) Inhalation Not Specified Dog Lungs 90 Day(s) Rat Inhalation Not Specified Lungs Lungs 90 Day(s) Monkey Inhalation Not Specified 90 Day(s) Rat Inhalation 15 ppm LOAEL Respiratory system

#### Amphotericin B

| 30 Day(s)  | Dog | Intravenous | 37 mg/kg/d  | lay LOA | AEL Kidney   |
|------------|-----|-------------|-------------|---------|--|
| 2 Month(s) | Dog | Intravenous | 16.5 mg/    | /kg/day | LOAEL Kidney   |
| 13 Week(s) | Rat | Oral 2 r    | mg/kg/day   | NOAEL   | Male reproductive system, Female reproductive system |
| 13 Week(s) | Dog | Oral 1.6    | 6 mg/kg/day | NOAEL   | Male reproductive system, Female reproductive system |

#### Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

#### Formaldehyde

Embryo / Fetal Development Mouse Oral 185 mg/kg/day Not teratogenic, Maternal toxicity Embryo / Fetal Development Rat Inhalation 40 ppm Not Teratogenic, Maternal Toxicity

#### Amphotericin B

Embryo / Fetal Development Rat Oral 7.5 mg/kg/day NOAEL Not teratogenic, Fetotoxicity Embryo / Fetal Development Rabbit Oral 10 mg/kg/day NOAEL Not Teratogenic, Fetotoxicity

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

#### Formaldehyde

*In Vitro* Bacterial Mutagenicity (Ames) Bacteria Positive *In Vitro* Chromosome Aberration Rodent Positive *In Vitro* Sister Chromatid Exchange Rodent Positive *In Vivo* Chromosome Aberration Not specified Positive

#### **Polymyxin B**

In Vitro Negative In Vivo Negative

#### **Amphotericin B**

Bacterial Mutagenicity (Ames)Salmonella , E. coliNegativeIn Vivo MicronucleusMouseNegativeIn Vitro Chromosome AberrationChinese Hamster Ovary (CHO) cellsNegative

## **11. TOXICOLOGICAL INFORMATION**

#### Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

| Formaldehyde                   |  |
|--------------------------------|--|
| 2 Year(s) Rat Inhalation 6 ppm | LOAEL Tumors   |
| 2 Year(s) Mouse Inhalation 15  | ppm LOAEL Tumors   |
| Carcinogen Status:             | None of the components present in this material at concentrations equal to or greater than 0.1% are listed by IARC, NTP, OSHA, or ACGIH as a carcinogen. |
| Formaldehyde                   |  |
| IARC:                          | Group 1 (Carcinogenic to Humans)   |
| NTP:                           | Known Human Carcinogen   |
| OSHA:                          | Listed   |
|                                |  |
|                                |  |

### **12. ECOLOGICAL INFORMATION**

| Environmental Overview:        | Environmental properties have not been thoroughly investigated. This product contains trace quantities of mercury, releases to the environment should be avoided. |
|--------------------------------|---|
| Toxicity:                      | No data available   |
| Persistence and Degradability: | No data available   |
| Bio-accumulative Potential:    | No data available   |
| Mobility in Soil:              | No data available   |

## **13. DISPOSAL CONSIDERATIONS**

Waste Treatment Methods:Dispose of waste in accordance with all applicable laws and regulations. Member State<br/>specific and Community specific provisions must be considered. Considering the relevant<br/>known environmental and human health hazards of the material, review and implement<br/>appropriate technical and procedural waste water and waste disposal measures to prevent<br/>occupational exposure and environmental release. It is recommended that waste minimization<br/>be practiced. The best available technology should be utilized to prevent environmental<br/>releases. This may include destructive techniques for waste and wastewater. This product<br/>contains trace quantities of mercury and may qualify as a RCRA Hazardous Waste. Status<br/>should be confirmed using the EPA Toxicity Characteristic Leaching Procedure (TCLP).

#### Formaldehyde

**RCRA - U Series Wastes** 

Listed

### **14. TRANSPORT INFORMATION**

#### The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

# **15. REGULATORY INFORMATION**

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications WHMIS hazard class: None required

#### **Neomycin B**

| CERCLA/SARA 313 Emission reporting            | Not Listed                         |
|---|------------------------------------|
| California Proposition 65                     | Not Listed                         |
| Australia (AICS):                             | Present                            |
| Standard for the Uniform Scheduling           | Schedule 4                         |
| for Drugs and Poisons:                        |                                    |
| EU EINECS/ELINCS List                         | 204-292-2                          |
|   | 204-232-2                          |
| Amphotericin B                                |                                    |
| CERCLA/SARA 313 Emission reporting            | Not Listed                         |
| California Proposition 65                     | Not Listed                         |
| Australia (AICS):                             | Present                            |
| Standard for the Uniform Scheduling           | Schedule 4                         |
| for Drugs and Poisons:                        | Schedule 4                         |
| EU EINECS/ELINCS List                         | 215-742-2                          |
| EU EINEGS/ELINGS LISI                         | 210-742-2                          |
| Polymyxin B                                   |                                    |
| CERCLA/SARA 313 Emission reporting            | Not Listed                         |
| California Proposition 65                     | Not Listed                         |
| EU EINECS/ELINCS List                         | 215-768-4                          |
|   | 210 700 4                          |
| Formaldehyde                                  |                                    |
| CERCLA/SARA 313 Emission reporting            | 0.1 %                              |
| CERCLA/SARA Hazardous Substances              | 100 lb                             |
| and their Reportable Quantities:              | 45.4 kg                            |
| CERCLA/SARA - Section 302 Extremely Hazardous | 500 lb                             |
| TPQs  |                                    |
| CERCLA/SARA - Section 302 Extremely Hazardous | 100 lb                             |
| Substances EPCRA RQs                          |                                    |
| California Proposition 65                     | carcinogen initial date 1/1/88 gas |
| OSHA - Specifically Regulated Chemicals       | 2 ppm                              |
|   | 0.5 ppm                            |
|   | 0.75 ppm                           |
| Inventory - United States TSCA - Sect. 8(b)   | Present                            |
| Australia (AICS):                             | Present                            |
|   | 1 rooont                           |

### Material Name: Triple-ET Innovator Revision date: 15-Apr-2014

Page 10 of 11 Version: 2.0

| 15. REGULATORY INFORMATION                          |  |  |
|---|--|--|
| Standard for the Uniform Scheduling                 | Schedule 2                                 |  |
| for Drugs and Poisons:                              | Schedule 6                                 |  |
| EU EINECS/ELINCS List                               | 200-001-8                                  |  |
| WESTERN EQUINE ENCEPHALOMYELITIS                    |  |  |
| CERCLA/SARA 313 Emission reporting                  | Not Listed                                 |  |
| California Proposition 65                           | Not Listed                                 |  |
| EU EINECS/ELINCS List                               | Not Listed                                 |  |
| Tetanus toxoid                                      |  |  |
| CERCLA/SARA 313 Emission reporting                  | Not Listed                                 |  |
| California Proposition 65                           | Not Listed                                 |  |
| Standard for the Uniform Scheduling                 | Schedule 4                                 |  |
| for Drugs and Poisons:                              |  |  |
| EU EINECS/ELINCS List                               | 297-262-3                                  |  |
| Adjuvant  |  |  |
| CERCLA/SARA 313 Emission reporting                  | Not Listed                                 |  |
| California Proposition 65                           | Not Listed                                 |  |
| EU EINECS/ELINCS List                               | Not Listed                                 |  |
| Venezuelan Equine Enchephalomyelitis                |  |  |
| CERCLA/SARA 313 Emission reporting                  | Not Listed                                 |  |
| California Proposition 65                           | Not Listed                                 |  |
| EU EINECS/ELINCS List                               | Not Listed                                 |  |
| EASTERN EQUINE ENCEPHALOMYELITIS                    |  |  |
| CERCLA/SARA 313 Emission reporting                  | Not Listed                                 |  |
| California Proposition 65                           | Not Listed                                 |  |
| EU EINECS/ELINCS List                               | Not Listed                                 |  |
| Thimerosal  |  |  |
| CERCLA/SARA 313 Emission reporting                  | Not Listed                                 |  |
| California Proposition 65                           | developmental toxicity initial date 7/1/90 |  |
| Inventory - United States TSCA - Sect. 8(b)         | Present                                    |  |
| Australia (AICS):                                   | Present                                    |  |
| <b>REACH - Annex XVII - Restrictions on Certain</b> | Use restricted. See item 18.               |  |
| Dangerous Substances:                               |  |  |
| EU EINECS/ELINCS List                               | 200-210-4                                  |  |
|   |  |  |

# **16. OTHER INFORMATION**

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

#### Material Name: Triple-ET Innovator Revision date: 15-Apr-2014

- H302 Harmful if swallowed
- H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled
- H317 May cause an allergic skin reaction
- H361 Suspected of damaging fertility or the unborn child
- H301 Toxic if swallowed
- H314 Causes severe skin burns and eye damage
- H350 May cause cancer
- H331 Toxic if inhaled
- H300 Fatal if swallowed
- H310 Fatal in contact with skin
- H330 Fatal if inhaled
- H373 May cause damage to organs through prolonged or repeated exposure
- H400 Very toxic to aquatic life
- H410 Very toxic to aquatic life with long lasting effects

Xn - Harmful Toxic to Reproduction: Category 3 T - Toxic C - Corrosive Carcinogenic: Category 3 T+ - Very toxic N - Dangerous for the environment

- R22 Harmful if swallowed.
- R63 Possible risk of harm to the unborn child.
- R34 Causes burns.
- R40 Limited evidence of a carcinogenic effect
- R33 Danger of cumulative effects.
- R42/43 May cause sensitization by inhalation and skin contact.
- R23/24/25 Toxic by inhalation, in contact with skin and if swallowed.
- R26/27/28 Very toxic by inhalation, in contact with skin and if swallowed.
- R50/53 Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

| Data Sources:         | The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.  |
|-----------------------|---|
| Reasons for Revision: | Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.<br>Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on<br>Ingredients. Updated Section 4 - First Aid Measures. Updated Section 6 - Accidental Release<br>Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls<br>/ Personal Protection. Updated Section 9 - Physical and Chemical Properties. Updated Section<br>11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 13 -<br>Disposal Considerations. Updated Section 16 - Other Information. |
| Prepared by:          | Toxicology and Hazard Communication   |

Zoetis Global Risk Management

Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet